Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAC-T cells targeting FAP (IL12 secreting)
- Development stage
- Unknown
- Lead developer
- Jinshazhou Hospital of Guangzhou University of Chinese Medicine
- Modality
- Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
TAC-T cells targeting FAP (IL12 secreting) is an adoptive cell therapy consisting of T-cells engineered with a T-cell Antigen Coupler (TAC) receptor designed to recognize Fibroblast Activation Protein (FAP). FAP is highly expressed on cancer-associated fibroblasts (CAFs) within the tumor microenvironment of various solid tumors. Unlike traditional CAR-T cells, TAC-T cells utilize the endogenous T-cell receptor (TCR) complex to initiate signaling, potentially offering a more controlled and physiological activation. This specific iteration is further engineered to secrete Interleukin-12 (IL-12), a potent pro-inflammatory cytokine intended to remodel the immunosuppressive tumor microenvironment, enhance T-cell persistence, and recruit other immune cells. It is being investigated, often in combination with other TAC-T products, for the treatment of advanced nasopharyngeal carcinoma and other solid tumors.
- Other names
- FAP-targeting TAC-T cells (IL-12 secreting)IL-12 secreting FAP-TAC-T cellsIL12 secreting FAP-TAC-T cellsIL 12 secreting FAP-TAC-T cells
02
Targets
FAP (Fibroblast activation protein alpha)IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on TAC-T cells targeting FAP (IL12 secreting).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAC-T cells targeting FAP (IL12 secreting).